Kaken Pharmaceutical completes acquisition of Aadi Subsidiary, Inc.

Kaken Pharmaceutical (TSE:4521) announced the completion of its acquisition of Aadi Subsidiary, Inc., a California-based company led by CEO David Lennon, effective March 26, 2025. The acquisition, initially disclosed on December 20, 2024, sees Aadi become a fully owned subsidiary of Kaken. Kaken financed the acquisition through a special purpose company, paying approximately $103 million to acquire all outstanding shares of Aadi from Whitehawk Therapeutics, Inc. (NASDAQ: WHWK). The move grants Kaken access to Aadi’s “FYARRO®” product, its rare disease sales platform, and related expertise. Kaken intends to leverage Aadi's capabilities to support the U.S. launch of its own investigational drug, "KP-001", for intractable vascular malformations. Kaken anticipates a minimal impact on its consolidated financial results for the fiscal year ending March 2025 from this acquisition.